September 02, 2022 | The American Prospect
There are numerous ways for the Biden administration to implement these safeguards. One option would be to issue a broad executive order that sets a path to restore public trust in the Patent Office. This order would require that the USPTO create a publicly available record of intervention in appeal proceedings by staff other than APJs, and outline new ethics practices that would ensure key USPTO staff recuse themselves from matters involving prior clients or former employers, and refrain from representing clients or working for companies whose cases they decide for at least three years.
July 16, 2021
Rumors that Delaware Senator Chris Coons (D-DE) has had a hand in nominating the new U.S. Patent and Trademark Office (USPTO) Director are extremely worrisome given Coons’ coziness with the Big Pharma industry and willingness to vote against his own party to benefit large corporations. Coons has a long record of proposing and passing legislation (often with far-right Republicans) to benefit Big Pharma companies, at the expense of consumers and small businesses. While harmful to the general public, Coons’ legislation has directly benefited his family’s medical device manufacturer, enriching himself. His record and blatant disregard for consumer welfare should exclude him from any conversations about executive branch personnel.